Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 11 - 20 of about 185   

Articles published

AZN 4,780.00 +59.50 (1.26%)
price chart
AstraZeneca plc: Why $4.20 Is The Magic Number
Executive compensation plans have always drawn shareholders criticism but AstraZeneca's (LSE: AZN) (NYSE: AZN.US) 'Azip' plan has been designed with shareholders in mind.
Related articles »  
Why I'd Sell AstraZeneca plc And Buy Shire PLC
Shire (LSE: SHP) and AstraZeneca (LSE: AZN) are two very different companies. On one hand, Shire is growing rapidly and has plenty of new drugs under development, which should drive sales growth.
Why Pfizer Inc. (PFE) May Not Bid For AstraZeneca plc (ADR) (AZN) Again?
Pfizer's main objective behind AstraZeneca plc (ADR) (NYSE:AZN) was to gain access to its cancer drugs pipeline. However, failure pushed Pfizer to look for alternatives.
Related articles »  
Baader Helvea Reiterates �Hold� Rating for AstraZeneca plc (AZN)
Baader Helvea restated their hold rating on shares of AstraZeneca plc (LON:AZN) in a report issued on Wednesday. They currently have a GBX 4,360 ($68.23) target price on the stock.
AstraZeneca plc's "Neutral" Rating Reaffirmed at Credit Suisse ...  Intercooler
AstraZeneca plc (AZN) - Research Analysts' Weekly Ratings Changes  sleekmoney
Related articles »  
Patent Cliff: A Lethal Blow To Big Pharma Or Just A Tiny Bump?
A success story in this regard is that of AstraZeneca, which is expected to file for marketing approvals for its cancer drug AZD9291 in 2015, in a record 2.5 years since enrollment by taking advantage of breakthrough therapy designation status granted ...
Deutsche Bank Reiterates "Hold" Rating for AstraZeneca plc (AZN)
AstraZeneca plc logo AstraZeneca plc (LON:AZN)'s stock had its �hold� rating reaffirmed by investment analysts at Deutsche Bank in a note issued to investors on Monday.
Will AstraZeneca plc's Acquisition Spree Help The Company Return To Growth?
AstraZeneca's (LSE: AZN) (NYSE: AZN.US) promise to increase revenues to $45bn by 2023 has been met with plenty of scepticism.
Related articles »  
AstraZeneca plc (AZN) Comments on Strategic Priorities Ahead of Investor ...
AstraZeneca plc (NYSE: AZN) will today provide an update for institutional investors and financial analysts on the progress against the company's strategic priorities of achieving scientific leadership and returning to growth.
AstraZeneca Plc' share price down, projects annual revenues of more than ...  Binary Tribune
AstraZeneca details organic growth plan (AZN)  Seeking Alpha (registration)
Related articles »  
AstraZeneca plc Now Covered by BNP Paribas (AZN)
AstraZeneca plc (NYSE:AZN) opened at 73.91 on Tuesday. AstraZeneca plc has a 52-week low of $56.12 and a 52-week high of $82.68.
Related articles »  
AstraZeneca plc Research Coverage Started at BNP Paribas (AZN)
BNP Paribas initiated coverage on shares of AstraZeneca plc (LON:AZN) in a research note released on Tuesday morning. The firm issued an outperform rating and a GBX 5,500 ($86.07) target price on the stock.